Branislav Ilic

Dr. Branislav Ilic

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2025 in Cancers
Verified
Journal Article
Open access
PDF file
VKVesna Ćeriman Krstić
Vesna Ćeriman Krstić
NSNatalija Vasilije Samardzic
Natalija Vasilije Samardzic
MSMihailo Stjepanovic
Mihailo Stjepanovic
SPSpasoje Popevic
Spasoje Popevic
TATatjana N Adzic-Vukicevic
Tatjana N Adzic-Vukicevic
JMJelena Milin-Lazovic
Jelena Milin-Lazovic
Introduction: Lung cancer remains the leading cause of cancer death among all cancers. The discovery of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations led to an increased survival rate in patients with locally advanced and metastatic non-small cell lung cancer (NSCLC). Results of the ALTA 1L study showed superior outcomes for patients treated with brigatinib compared to patients treated with crizotinib. Background: We conducted research including 23 patients with ALK-positive lung adenocarcinoma who were treated with brigatinib in first or further lines of therapy. The median follow-up was 22 months (4–66 months). Results: There were no significant differences in patient population between the first and further lines of treatment regarding sex distribution (p = 0.692), smoking status (p = 0.554), ECOG performance status (p = 1.000), and baseline presence of brain metastases (p = 0.862). The response rate was 47.8%, and disease control was 95.6%. The 12-month progression-free survival (PFS) and overall survival (OS) rates were 85.3% and 86.5%, respectively, while the 60-month PFS rate was not reached, and the 60-month OS rate was 27.1%. The mPFS and mOS were 32 months. Conclusions: The results of this analysis are promising, as our patients experienced better outcomes compared to those in the ALTA 1L study, which may be attributed to the small sample size. However, the effectiveness of brigatinib has been confirmed in our clinical practice.

7 March 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
SPSpasoje Popevic
Spasoje Popevic
NMNikola Marić
Nikola Marić
BIBranislav Ilic
Branislav Ilic
SBSlobodan Belić
Slobodan Belić
IRIvana Sekulovic Radovanovic
Ivana Sekulovic Radovanovic
MSMihailo Stjepanovic
Mihailo Stjepanovic
Glucose is the main source of energy in human cells. Elevated levels of glucose are one of the most common metabolic disorders, and it has been shown to have a significant, mostly negative, effect on multiple chronic and acute diseases. Lung cancer remains one of the biggest challenges for treatment in modern medicine, with a high prevalence, incidence and mortality. Hyperglycemia is not uncommon in patients with lung cancer; however, it is usually overlooked. Patients with unregulated glycemia and lung cancer have been shown to have worse outcomes, reduced therapeutic effect and more complications during treatment. Studies have identified multiple molecular pathways common in both hyperglycemia and lung cancer; however, no clear correlation has been identified. By understanding these signaling pathways, we can influence the outcome therapeutically and thereby improve the survival of patients with lung cancer.

7 April 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
VKVesna Ćeriman Krstić
Vesna Ćeriman Krstić
NSNatalija Vasilije Samardzic
Natalija Vasilije Samardzic
SPSpasoje Popevic
Spasoje Popevic
RSRuza Stevic
Ruza Stevic
BIBranislav Ilic
Branislav Ilic
JMJelena Milin-Lazovic
Jelena Milin-Lazovic
Background/Objectives: Patients with stage III non-small cell lung cancer represent a very heterogeneous group of patients. In the past, the standard of care for patients with inoperable stage III non-small cell lung cancer was concurrent or sequential radical radiotherapy and chemotherapy. But the progression-free survival was 8 months, and the 5-year overall survival rate was less than 20%. After the results of the PACIFIC study, the standard of care for this group of patients is chemoradiotherapy with durvalumab as consolidation therapy. The aim of our study was to evaluate the efficacy of consolidation durvalumab in a real-world setting after sequential CRT. Methods: We included 24 patients with unresectable stage III non-small cell lung cancer who did not progress after sequential chemoradiotherapy and who received durvalumab consolidation. Results: Median progression-free survival was 16 months, 95% CI (0.5–31.5), and median overall survival was 20 months, 95% CI (13.4–26.6 months). The twelve-month progression-free survival and overall survival rate were 55.1% and 68%, respectively, and the 18-month progression-free survival and overall survival rates were 44.1% and 56.5%, respectively. Conclusions: Durvalumab introduced a new era in the treatment of patients with unresectable stage III non-small cell lung cancer with a significantly prolonged 5-year overall survival rate. Our study is one of the few that investigated the efficacy of durvalumab in a real-world setting after sequential CRT. Our results showed that durvalumab is effective in patients who were treated with sequential CRT. However, the time between radiotherapy termination and the start of durvalumab should be shorter.

22 January 2026 in Medicina
Verified
Journal Article
Open access
PDF file
NTNikola Trboljevac
Nikola Trboljevac
SDSanja Dimic-Janjic
Sanja Dimic-Janjic
Milica KontićMilica Kontić
Milica Kontić
MOMaja Omčikus
Maja Omčikus
BIBranislav Ilic
Branislav Ilic
DNDragana Nenezic
Dragana Nenezic
Background and Objectives: Idiopathic pulmonary fibrosis (IPF) is a progressive, unpredictable, fatal interstitial lung disease. Antifibrotic therapy with pirfenidone or nintedanib slows functional decline, yet comparative real-world evidence remains limited. Materials and Methods: This retrospective, single-center, comparative cohort study included 76 IPF patients treated at the Clinic for Pulmonology at the University Clinical Center of Serbia (February 2019–February 2025). Diagnosis of IPF was made according to the guidelines of the American Thoracic Society and the European Respiratory Society. Demographic features, comorbidities, forced vital capacity (FVC), diffusion capacity for carbon monoxide (DLCO), high-resolution computerized tomography (HRCT) patterns, 6-min walk test distance (6MWTD), echocardiography, and survival outcomes were analyzed. Disease progression was defined as a ≥10% decline in FVC and/or DLCO after 12 months. Results: Of the 76 patients, 31 received nintedanib and 45 pirfenidone. Baseline characteristics, comorbidities, and HRCT patterns were comparable between groups. Mean annual decline in FVC was −1.74% with pirfenidone and −2.38% with nintedanib, without a statistical difference. DLCO declined by −4.25% and −6.29%, respectively, with similar downward trends over time in both groups. Progression was recorded in 35 (46.1%) patients, of whom 18 (58.06%) were in the nintedanib group and 17 (37.77%) in the pirfenidone group, with no difference between therapies (p = 0.81). Definite and probable usual interstitial pneumonia (UIP) were evenly represented on HRCT, although progression correlated significantly with the probable UIP pattern (p = 0.006). 6MWTD decreased in both groups over 12 months, again without treatment-related differences (p = 0.566). During up to 6 years of follow-up, overall survival was 4.18 years, with no significant difference between the nintedanib (4.55 years) and pirfenidone (3.81 years) groups (p = 0.159). No association was found between disease stage (FVC or DLCO) and progression. Conclusions: This study demonstrates that pirfenidone and nintedanib are equally effective in the management of IPF in real-world settings. The absence of significant differences in functional decline, progression rates, and survival indicates that treatment choices should be guided by individual clinical profiles rather than efficacy alone, reinforcing antifibrotic therapy as the primary approach to alter the course of IPF. Importantly, disease progression was strongly associated with a probable UIP pattern on HRCT, supporting current guidelines suggesting that probable UIP has a natural history and prognosis similar to those of definite UIP.

1 January 2026 in Srpski arhiv za celokupno lekarstvo
Verified
Journal Article
Open access
PDF file
SPSpasoje Popevic
Spasoje Popevic
NLNensi Lalic
Nensi Lalic
Marko BojovićMarko Bojović
Marko Bojović
RMRade Milic
Rade Milic
LILalić Ivica
Lalić Ivica
DKDane Krtinic
Dane Krtinic
Long-term statistical data worldwide on lung cancer (LC) show an overall 34% reduction in mortality compared to 1991. The primary reasons for this decline include a reduced smoking rate, earlier diagnosis, advancements in invasive diagnostic methods, and the introduction of low-dose computed tomography screening. These factors have contributed to detecting LC at earlier stages of the disease and improving timely treatment. The diagnostic sensitivity of conventional bronchoscopy for peripheral pulmonary lesions (PPL), representing early-stage LC, has historically been relatively low, ranging 30?60%. Over the past two decades, diagnostic sensitivity for PPL has improved with the development of advanced navigational techniques, such as virtual bronchoscopic navigation, electromagnetic navigation bronchoscopy, radial endobronchial ultrasound, cone-beam computed tomography, and ultrathin bronchoscopy. In the past two to three years, robotic-assisted bronchoscopy has further enhanced diagnostic navigation capabilities to their current maximum potential.

Verified
Journal Article
Open access
PDF file
NDNatasa Djurdjevic
Natasa Djurdjevic
MPMarija Dusanovic Pjevic
Marija Dusanovic Pjevic
MSMihailo Stjepanovic
Mihailo Stjepanovic
NCNikola Colic
Nikola Colic
SDSanja Dimic-Janjic
Sanja Dimic-Janjic
MGMilka Grk
Milka Grk
Progressive pulmonary fibrosis (PPF) comprises interstitial lung diseases characterized by progressive fibrosis and lung function decline. Nintedanib slows disease progression by inhibiting FGFR, VEGFR, and PDGFR signaling, but treatment response varies among patients. We investigated whether VEGFR2, PDGFRB, and TGFB1 gene variants are associated with nintedanib treatment outcomes, including changes in pulmonary function, diffusing capacity and adverse effects. This prospective study included 75 patients with PPF diagnosed according to ATS/ERS/JRS/ALAT criteria and treated with nintedanib at the Clinic of Pulmonology, University Clinical Center of Serbia. Spirometry and diffusing capacity were assessed at baseline and after 6 and 12 months. Genotyping of VEGFR2 rs2071559 and rs1870377; PDGFRB rs2302273, rs2229562, and rs246395; and TGFB1 rs1800470 was performed using TaqMan® assays. Carriers of the PDGFRB rs2302273 A allele more frequently experienced gastrointestinal adverse events (45.2% vs. 20.5%; p = 0.022; OR 3.2, 95% CI 1.156–8.866) and diarrhea (38.7% vs. 15.9%; p = 0.026; OR 3.3, 95% CI 1.129–9.869). Patients with the PDGFRB rs246395 TT genotype more frequently had a ≥15% decline in DLCO after one year (46% vs. 22%; p = 0.038; OR 3.0, 95% CI 1.045–8.394). No significant associations were observed for the analyzed VEGFR2 or TGFB1 variants. These findings suggest that PDGFRB variants may be associated with nintedanib treatment outcomes, although confirmation in larger cohorts is needed.